Analytical Data
-
Gene name
GLP2
- Application
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P55095
-
Expression Region
His146~Asp178
-
Molecular Weight
37kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Glucagon-like peptide-2 (GLP-2) is an intestinal hormone produced in response to food intake, playing a crucial role in gut health and metabolism. Research on GLP-2 has gained significant attention due to its potential therapeutic applications in various gastrointestinal disorders, such as short bowel syndrome, inflammatory bowel disease, and intestinal ischemia. GLP-2 promotes intestinal growth, enhances nutrient absorption, and reduces inflammation, making it a critical factor in maintaining the integrity of the intestinal epithelium. The development of recombinant GLP-2 protein has opened new avenues for clinical applications, enabling more precise dosing and better patient outcomes. Additionally, understanding the signaling pathways and mechanisms through which GLP-2 exerts its effects can lead to innovative treatments for a range of conditions associated with intestinal dysfunction. As researchers continue to explore the therapeutic potential of GLP-2, including its role in metabolism and obesity, the implications for patient care and management of gastrointestinal diseases are becoming increasingly clear. Thus, GLP-2 recombinant protein represents a promising area of study in both basic and applied biomedical research.
